However, most of these efforts involved targeting of several enzymes downstream of the EWS/FLI1 fusion protein, such as IGF1R, and did not attempt to modulate the activity of this likely most crucial factor for ES oncogenesis itself. The gene discussed is FLI1; the disease is Ewing sarcoma.